Efficacy and Safety of Mometasone Furoate Nasal Spray in Children With Adenoid Hypertrophy. SNORE Study (P05155)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00552032
First received: October 31, 2007
Last updated: April 29, 2014
Last verified: April 2014

October 31, 2007
April 29, 2014
August 2007
January 2010   (final data collection date for primary outcome measure)
Change From Baseline in Adenoid/Choana (A/C) Index Grade [ Time Frame: Baseline (visit 2), Weeks 4 (visit 3), Week 8 (visit 4) ] [ Designated as safety issue: No ]
Changes in adenoid size were assessed by nasopharyngoscopic examination and were determined using the Adenoid/Choana (A/C) Index. Grades were assigned to intervals of A/C ratio percentages: grade I (0-25%), II (26-50%), III (51-75%) and IV (76-100%). Changes in adenoid size were expressed as the mean difference between grades at baseline and study visit. Positive values indicated a decrease in adenoid size, a 0 value indicated that size remained the same, and negative values indicated an increase in adenoid size.
Size reduction of the adenoids from Baseline as graded by Nasopharyngoscopic evaluation (Adenoid/Choana A/C Index) [ Time Frame: Between Baseline and end of treatment (week 8) ]
Complete list of historical versions of study NCT00552032 on ClinicalTrials.gov Archive Site
  • Total Severity Symptom Scores: Morning and Evening (AM & PM) [ Time Frame: Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) ] [ Designated as safety issue: No ]
    Symptoms were assessed by whole-number linear scale to grade their severity. Scores were recorded AM & PM (12 hours later) & were based on severity within 12 hours of prior recording. The following symptoms were evaluated: Snoring; Nasal obstruction & discharge; Breathing difficulty; Oral respiration; Ear pain. Severity was graded according to the following scale: 0=absent; 1=mild; 2=moderate; 3=severe. Severity was scored individually and summed to obtain the Total Symptom Severity Score. The maximum total score possible was 36 daily; 18 for both AM (6 symptoms times max severity of 3)and PM.
  • Total Frequency Symptom Scores: AM & PM [ Time Frame: Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) ] [ Designated as safety issue: No ]

    Symptoms were assessed by whole-number linear scale to grade their frequency. Scores were recorded AM & PM (12 The following signs/symptoms were evaluated:

    Snoring; Nasal obstruction; and nasal discharge; Breathing difficulty; Oral respiration; Ear pain.

    Frequency was graded according to the following scale:

    0=absent; 1=intermittent; 2=persistent

    The frequency of symptoms was scored individually and summed to obtain the Total Frequency Symptom Score. The maximum total score possible was 24 daily; 12 for both AM (6 symptoms times max frequency of 2) and PM.

  • Number of Participants With Bilateral Tympanogram Results of: Normal, Abnormal, or Not Done [ Time Frame: Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) ] [ Designated as safety issue: No ]
    Tympanometry was performed in children ages 2-11 by certified audiologists. Results were categorized based on audiologist's assessment as either being normal (normal pressure in the middle ear with normal mobility of the eardrum and the conduction bones) , abnormal (abnormal pressure in the middle ear and/or abnormal mobility of the eardrum and the conduction bones), or tympanometry was not done (evaluation not completed). Results were assessed at baseline, Week 4 (Visit 3), and endpoint Week 8 (end of treatment).
  • Number of Participants With Otoscopic Results of: Normal or Abnormal [ Time Frame: Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) ] [ Designated as safety issue: No ]
    Otoscopic examination was performed of the right and left ear canals at baseline (visit 2) and each visit throughout treatment (visit 3 and visit 4). Results were categorized based on audiologist's assessment as either being normal (ear canal structures appear normal) or abnormal (ear canal structures appear abnormal).
  • Number of Participants With Rhinoscopic- Septum Results of: Aligned, Non-Obstructive, or Obstructive Deviation [ Time Frame: Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) ] [ Designated as safety issue: No ]
    Rhinoscopic examination of the septum was performed at baseline (visit 2) and each visit throughout treatment (visit 3 and visit 4). Results were categorized based on investigator's assessment as either being aligned (septum is aligned), non-obstructive (septum is not aligned but the deviation is non-obstructive), or obstructive (septum is deviated and obstructive) deviation.
  • Number of Participants With Rhinoscopic-Inferior Turbinates Results of: Normal, Hypertrophic, and Hypotrophic [ Time Frame: Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) ] [ Designated as safety issue: No ]
    Rhinoscopic examination of the inferior turbinates was performed at baseline (visit 2) and each visit throughout treatment (visit 3 and visit 4). Results were categorized based on investigator's assessment as either being normal appearance (normal size) , hypertrophic (swollen/normal size increased), or hypotrophic (normal size diminished).
  • Number of Participants With Rhinoscopic- Middle Meatus Results of: Patent, Partial Obstruction or Total Obstruction [ Time Frame: Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) ] [ Designated as safety issue: No ]
    Rhinoscopic examination of the middle meatus was performed at baseline (visit 2) and each visit throughout treatment (visit 3 and visit 4). Results were categorized based on investigator's assessment into 3 categories: patent (easily observed), partial obstruction (partially blocked from view), or total obstruction (completely blocked from view).
  • Rhinomanometry Results- Left and Right Nasal Fossa: Inspiratory Resistance [ Time Frame: Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) ] [ Designated as safety issue: No ]

    Rhinomanometry examination of the left & right Nasal Fossa was performed at baseline (visit 2) and each visit throughout treatment (visit 3 and visit 4) in participants ages 7-11 years.

    Rhinomanometry is a test of nasal function that measures air pressure and the rate of airflow in the nasal airway during respiration by means of equipment. These findings were used to calculate inspiratory nasal airway resistance reported in Pascal/centimeter^3/second (Pa/cm^3/sec).

  • Rhinomanometry Results- Left and Right Nasal Fossa: Expiratory Resistance [ Time Frame: Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) ] [ Designated as safety issue: No ]

    Rhinomanometry examination of the left & right Nasal Fossa was performed at baseline (visit 2) and each visit throughout treatment (visit 3 and visit 4) in participants ages 7-11 years.

    Rhinomanometry is a test of nasal function that measures air pressure and the rate of airflow in the nasal airway during respiration by means of equipment. These findings were used to calculate expiratory nasal airway resistance reported in Pascal/centimeter^3/second (Pa/cm^3/sec).

  • Rhinomanometry Results- Left and Right Nasal Fossa: Inspiration Flow at 75 Pa [ Time Frame: Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) ] [ Designated as safety issue: No ]

    Rhinomanometry examination of the left & right Nasal Fossa was performed at baseline (visit 2) and each visit throughout treatment (visit 3 and visit 4) in participants ages 7-11 years.

    Rhinomanometry is a test of nasal function that measures air pressure and the rate of airflow in the nasal airway during respiration by means of equipment. Inspiration flow was calculated at 75 Pa.

  • Rhinomanometry Results- Left and Right Nasal Fossa: Expiratory Flow at 75 Pa [ Time Frame: Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) ] [ Designated as safety issue: No ]

    Rhinomanometry examination of the left & right Nasal Fossa was performed at baseline (visit 2) and each visit throughout treatment (visit 3 and visit 4) in participants ages 7-11 years.

    Rhinomanometry is a test of nasal function that measures air pressure and the rate of airflow in the nasal airway during respiration by means of equipment. Expiratory flow was calculated at 75 Pa.

  • Number of Participants With Pure-Tone Audiometric Results of: Normal, Abnormal, or Not Done [ Time Frame: Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) ] [ Designated as safety issue: No ]
    Pure-tone audiometry was performed in children ages 7-11 by certified audiologists. Results were categorized based on audiologist's assessment as either being normal (within normal limits), abnormal (outside normal limits), or audiometry was not done (not performed). Results were assessed at baseline, Week 4 (Visit 3), and endpoint Week 8 (end of treatment).
  • Acoustic Rhinometry Results- Minimal Cross-Sectional Area: Left and Right Nasal Fossa [ Time Frame: Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) ] [ Designated as safety issue: No ]

    Acoustic rhinometry examination of the left & right Nasal Fossa was performed by principal investigators at baseline & each visit throughout treatment in participants ages 7-11 years. Acoustic rhinometry is a technique intended for assessment of the geometry of the nasal cavity and nasopharynx and for evaluating nasal obstruction. The technique is based on an analysis of sound waves reflected from the nasal cavities.

    Measurements were taken for each side of the nose (nasopharyngeal minimum cross-sectional area) & were reported in cm^3.

  • Acoustic Rhinometry Results- Nasopharyngeal Volume (NPV): Left and Right Nasal Fossa [ Time Frame: Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) ] [ Designated as safety issue: No ]
    Acoustic rhinometry examination of the left & right Nasal Fossa was performed by principal investigators at baseline & each visit throughout treatment in participants ages 7-11 years. Acoustic rhinometry is a technique intended for assessment of the geometry of the nasal cavity and nasopharynx and for evaluating nasal obstruction. The technique is based on an analysis of sound waves reflected from the nasal cavities.
  • Number of Participants With Pediatric Sleep Questionnaire (PSQ)- Impact on Health-Related Quality of Life (HRQL) Results of: Mild, Moderate, or Severe [ Time Frame: Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) ] [ Designated as safety issue: No ]
    PSQ consists of 90 variables divided into 3 different factors:snoring, somnolence, and behavior. All positive Snoring and Somnolence answers scored with Yes=1 and No=0, and scores averaged to obtain a total score between 0.00 and 1.00. Behavior factor scored between 1-3, and scores averaged for total score of 1 to 3. Increased scores indicate increasing abnormality of sleep. Based on determined cut-offs, participants were categorized as having mild, moderate, or severe discomfort due to interference of sleep.
  • Quality of Life Questionnaire (PedsQL) Total Score (Ages 2-4) [ Time Frame: Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) ] [ Designated as safety issue: No ]
    The impact on quality of life (QOL) was measured by a general pediatric health questionnaire. Versions were self-administered & answered by participants' parents. This modular instrument consists of 21 items using a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, & school functioning) are scored. Total score is sum of all the items over the number of items answered on all the scales. Higher scores indicate a better health related QOL.
  • Quality of Life Questionnaire (PedsQL) Total Score (Ages 5-7) [ Time Frame: Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) ] [ Designated as safety issue: No ]
    The impact on quality of life (QOL) was measured by a general pediatric health questionnaire. Versions were self-administered & answered by participants' parents. Questionnaire consists of 23 items using a 3-point scale: from 0 (not at all), 2 (sometimes), 4 (a lot). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, & school functioning) are scored. Total score is sum of all the items over the number of items answered on all the scales. Higher scores indicate a better health related QOL.
  • Quality of Life Questionnaire (PedsQL) Total Score (Ages 8-12) [ Time Frame: Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) ] [ Designated as safety issue: No ]
    The impact on quality of life (QOL) was measured by a general pediatric health questionnaire. Versions were self-administered & answered by participants' parents. This modular instrument consists of 23 items using a 5-point scale: from 0 (never) to 4 (almost always). Items are reversed scored and linearly transformed to a 0-100 scale as follows: 0=100, 1=75, 2=50, 3=25, 4=0. 4 dimensions (physical, emotional, social, & school functioning) are scored. Total score is sum of all the items over the number of items answered on all the scales. Higher scores indicate a better health related QOL.
  • Obstructive Sleep Apnea-18 (OSA-18) Questionnaire Total Score [ Time Frame: Baseline (Visit 2), Week 4 (Visit 3), Week 8 (Visit 4) ] [ Designated as safety issue: No ]

    18 items of the survey were graded on a 7-point ordinal scale. Caregivers were asked to describe how often in the last 4 weeks had the child exhibited specific symptoms according to the following scale: 1: none of the time; 2: hardly any of the time; 3: a little of the time; 4: some of the time; 5: a good bit of the time; 6: most of the time; 7: all of the time. All scores were summed (total score: 18-126).

    Grading was as follows:

    • Scores < 60 suggest a slight impact on health related quality of life (HRQL)
    • Scores 60-80 suggest a moderate impact
    • Scores over 80 suggest a great impact
  • Improvement in AM and PM Symptoms Score (snoring, nasal obstruction, oral breathing, ear pain, nasal discharge and difficulty breathing) as evaluated by the parent or patient. [ Time Frame: 8 week treatment period followed by 16 week follow-up ]
  • Improvement in the Rhinomanometry, Pure Tone Audiogram and Acoustic Rhinometry measurements in children ages 7 to 11 years old from baseline to end of treatment (week 8) and end of follow up (week 24). [ Time Frame: From baseline to end of treatment (week 8) and end of follow up (week 24) ]
  • Pediatric Sleep Questionnaire (PSQ, Spanish) improvement from baseline to end of treatment (week 8) and end of follow up (week 24). [ Time Frame: From baseline to end of treatment (week 8) and end of follow up (week 24) ]
  • Pediatric QOL Questionnaire (PedsQL, Spanish) and Pediatric OSA-18 improvement from baseline to end of treatment (week 8) and end of follow up (week 24). [ Time Frame: From baseline to end of treatment (week 8) and end of follow up (week 24) ]
  • Improvement in the Otoscopic and Rhinoscopic examination. [ Time Frame: Between Baseline and end of treatment (week 8) ]
  • Improvement in measures of Bilateral Tympanogram in children 2 to 11 years old from baseline to end of treatment (week 8) and end of follow up (week 24). [ Time Frame: From baseline to end of treatment (week 8) and end of follow up (week 24) ]
  • Adverse events (related and concurrent) incidence. [ Time Frame: 8 week treatment period followed by 16 week follow-up ]
  • Incidence of adenoid hypertrophy recurrence during blinded follow-up extension period via Nasopharyngoscopic evaluation every 2 months. [ Time Frame: Every 2 months ]
Not Provided
Not Provided
 
Efficacy and Safety of Mometasone Furoate Nasal Spray in Children With Adenoid Hypertrophy. SNORE Study (P05155)
A Double-blind Placebo-controlled, Randomized, Parallel-group, Multicenter Clinical Trial to Evaluate Efficacy and Safety of Mometasone Furoate Nasal Spray in Children With Adenoid Hypertrophy SNORE Study

The purpose of this study is to determine whether 8 weeks treatment with mometasone furoate nasal spray (MFNS), twice daily, is safe and effective in treating adenoid hypertrophy in children.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Treatment
Adenoids Hypertrophy
  • Drug: Mometasone Furoate nasal spray
    Mometasone Furoate nasal spray 1 puff (50 mcg) per nostril twice daily x 8 weeks. There was a blinded follow-up period of 16 weeks, resulting in study duration of 24 weeks (6 months).
    Other Name: SCH 032088
  • Drug: Placebo
    Placebo nasal spray 1 puff per nostril twice daily x 8 weeks. There was a blinded follow-up period of 16 weeks, resulting in study duration of 24 weeks (6 months).
  • Experimental: Mometasone Furoate nasal spray
    Intervention: Drug: Mometasone Furoate nasal spray
  • Placebo Comparator: Placebo
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
132
January 2010
January 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Participants and their parents must demonstrate willingness to participate and comply with study procedures. Parents must sign a written informed consent
  • Participants and their parents must understand and be able to adhere to dosing and visit schedules, and agree to record symptom severity scores, medication times, and concomitant medications accurately and consistently in a daily diary
  • Children with a history of adenoid hypertrophy for at least 3 months with no response to previous medical treatment
  • Baseline adenoid tissue size must have been graded by nasopharyngoscopy examination as Grade III or IV on the Adenoid/Choana (A/C) Index (between 50% and 100% obstruction)
  • Baseline Total Severity Symptoms Score must be ≥ 8 points (AM or PM)
  • For inclusion in endpoints relating to otitis media with effusion (OME), participant must have persistent middle ear effusion for the past 3 months or more documented by otoscopic examination, middle ear pressure less than -150 mm H2O, Jerger type B flat tympanogram, and mild-moderate conductive hearing loss in audiometry supporting the diagnosis of OME

Exclusion Criteria:

  • Participants with previous surgery of hypertrophic adenoids with or without tympanostomy tube placement
  • Participants treated with inhaled or systemic corticosteroids within the past 1 month
  • Participants with Morbid Obesity (Body Mass Index >95 percentile of charts from the Centers for Disease Control)
  • Participants who have not accomplished the designated washout periods for any of the prohibited medications
  • Participants who have used any investigational products within the last 30 days
  • Participants who have used any antibodies for allergies in the past 90 days
  • Participants who have any abnormal physical examination results that may affect study evaluations or participant safety in the investigator's judgment
  • Participants who are allergic or have an idiosyncratic reaction to corticosteroids
  • Participants with signs and symptoms of acute or chronic bacterial rhinosinusitis
  • Participants has had an upper or lower respiratory tract or sinus infection that required antibiotic therapy with the last dose later than 14 days prior to screening, or who has had a viral upper or lower respiratory infection within 7 days prior to screening
  • Participants with a documented immunodeficiency condition
  • Participants with nasal structural abnormalities, including large nasal polyps and marked septum deviation that significantly interferes with nasal airflow
  • Participants with any clinically significant metabolic, cardiovascular, neurologic, hematologic, gastrointestinal, cerebrovascular, or respiratory disease (other than asthma), or any other disorder which, in the judgment of the Investigator, may interfere with the study evaluations or affect participant safety
Both
2 Years to 11 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00552032
P05155
No
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP